Serina Therapeutics Inc (SER)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -19,215 | -11,207 | 5,269 | -10,462 | -8,579 |
| Depreciation Amortization | 131 | 539 | 90 | 3,269 | 1,245 |
| Accounts receivable | N/A | 65 | N/A | 21 | 128 |
| Accounts payable and accrued liabilities | 1,197 | -1,661 | N/A | N/A | N/A |
| Other Working Capital | 1,470 | -3,316 | 81 | 329 | -884 |
| Other Operating Activity | -1,538 | -1,557 | -7,916 | 904 | 235 |
| Operating Cash Flow | $-17,955 | $-17,137 | $-2,476 | $-5,939 | $-7,855 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -59 | -22 | -504 | N/A | N/A |
| Other Investing Activity | 0 | 0 | 0 | 0 | 666 |
| Investing Cash Flow | $-59 | $-22 | $-504 | $N/A | $666 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 4,913 | N/A | 10,100 | N/A | N/A |
| Debt Repayment | N/A | -168 | -48 | N/A | N/A |
| Common Stock Issued | 7,559 | 10,000 | 15 | N/A | 496 |
| Other Financing Activity | 4,940 | 3,380 | 0 | 6,000 | 6,750 |
| Financing Cash Flow | $17,412 | $13,212 | $10,067 | $6,000 | $7,246 |
| Exchange Rate Effect | -14 | N/A | N/A | N/A | N/A |
| Beginning Cash Position | 3,672 | 7,619 | 532 | 634 | 577 |
| End Cash Position | 3,056 | 3,672 | 7,619 | 695 | 634 |
| Net Cash Flow | $-616 | $-3,947 | $7,087 | $61 | $57 |
| Free Cash Flow | |||||
| Operating Cash Flow | -17,955 | -17,137 | -2,476 | -5,939 | -7,855 |
| Capital Expenditure | -59 | -22 | -504 | N/A | N/A |
| Free Cash Flow | -18,014 | -17,159 | -2,980 | -5,939 | -7,855 |